PRTN3 and Sjogren syndrome: Underlining the predictive capacity of ACPA, a large cohort of primary Sjögren syndrome patients was tested, and 9% of the patients were shown to be ACPA-positive, with more than half of them subsequently developing RA in the following 5 years [22].